Advertisement
Canada markets close in 2 hours 49 minutes

  • S&P/TSX

    21,974.49
    +89.11 (+0.41%)
     

  • S&P 500

    5,110.86
    +62.44 (+1.24%)
     

  • DOW

    38,306.46
    +220.66 (+0.58%)
     

  • CAD/USD

    0.7314
    -0.0009 (-0.13%)
     

  • CRUDE OIL

    83.83
    +0.26 (+0.31%)
     

  • Bitcoin CAD

    86,931.02
    -1,626.94 (-1.84%)
     

  • CMC Crypto 200

    1,325.56
    -70.97 (-4.88%)
     

  • GOLD FUTURES

    2,345.30
    +2.80 (+0.12%)
     

  • RUSSELL 2000

    2,003.48
    +22.37 (+1.13%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • NASDAQ

    15,965.21
    +353.45 (+2.26%)
     

  • VOLATILITY

    15.06
    -0.31 (-2.02%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research

GW Pharmaceuticals PLC (GWPH) closed at $175.80 in the latest trading session, marking a -0.01% move from the prior day. This change lagged the S&P 500's daily gain of 0.95%. Elsewhere, the Dow gained 0.94%, while the tech-heavy Nasdaq added 0.8%.

Prior to today's trading, shares of the company had lost 6.08% over the past month. This has lagged the Medical sector's gain of 5.28% and the S&P 500's gain of 2.47% in that time.

GWPH will be looking to display strength as it nears its next earnings release. In that report, analysts expect GWPH to post earnings of -$0.13 per share. This would mark year-over-year growth of 89.68%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.37 million, up 1731.5% from the year-ago period.

It is also important to note the recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. GWPH is currently a Zacks Rank #2 (Buy).

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.